Syndax Pharmaceuticals Insider Sells Shares
Botwood Nicholas A.J. sold 34,280 shares of Syndax Pharmaceuticals on June 11, 2026.
Key Points
- Botwood Nicholas A.J., Head of R&D, CMO at Syndax Pharmaceuticals, sold 34,280 shares for $617,040 on June 11, 2026.
- Syndax Pharmaceuticals' stock traded around $18.26 with a market cap of $1.62 billion and a 52-week range of $8.59 to $25.59.
- Analysts maintain a strong buy consensus with a mean target price of $39, following recent insider trading activities.
On June 11, 2026, Botwood Nicholas A.J., who serves as the Head of R&D and Chief Medical Officer at Syndax Pharmaceuticals, Inc. (NasdaqGS: SNDX), sold 34,280 shares of the company. The transaction, which was planned, took place at an average price of $18.00 per share, amounting to a total value of $617,040.
Insider Buying and Selling at Syndax Pharmaceuticals, Inc.
Botwood's transaction on June 11 wasn't his only recent activity. On June 12, he executed multiple transactions, including buying back 31,235 shares at various prices, indicating a dynamic trading strategy. These transactions were not planned under Rule 10b5-1 plans, suggesting they were discretionary trades.
Other Institutional Activity in Syndax Pharmaceuticals
Among institutional investors, BlackRock, Inc. increased its position by 15,424 shares, ending with 8,254,426 shares valued at approximately $192.8 million. Meanwhile, Goldman Sachs Group Inc. reduced its stake by 698,588 shares, bringing its holdings to 4,996,787 shares worth about $116.7 million. State Street Corp also trimmed its position by 166,476 shares, now holding 4,430,076 shares valued at around $103.5 million.
Syndax Pharmaceuticals Stock Snapshot
Shares of Syndax Pharmaceuticals are currently trading near $18.26. The company has a market capitalization of approximately $1.62 billion. Despite not being profitable, with a negative forward P/E ratio of -33.50, the stock has shown a 52-week range between $8.59 and $25.59. It has a 50-day moving average of $20.93 and a 200-day moving average of $19.45.
Analysts Set New Price Targets
Analysts remain optimistic about Syndax Pharmaceuticals. On May 22, 2026, HC Wainwright & Co. reiterated a 'buy' rating with a $40 price target. UBS and Barclays also maintained 'buy' ratings with targets of $37, while Citigroup set the highest target at $57. The consensus among 12 analysts is a strong buy, with a mean price target of $39.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc. is a biotechnology firm based in New York, focusing on developing cancer therapies. Its leading projects include Revuforj, a treatment for acute leukemia, and Niktimvo, aimed at chronic graft-versus-host disease. The company, led by CEO Michael A. Metzger, employs 298 people and operates in the healthcare sector.
Bottom Line
Insider transactions like Botwood's can offer insights into company leadership's view on stock valuation. Syndax Pharmaceuticals continues to attract attention from institutional investors and analysts, keeping it on the radar for those following the biotechnology sector. As always with 13F filings and insider trades, these reports reflect past actions and may not indicate current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.